Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Onyvax licenses anticancer vaccine from CRCT

May 17, 1999

Ligand confirms that ECOG has initiated multicenter phase II study of Ontak for NHL

May 13, 1999

Promising phase I/II results for Leuvectin in prostate cancer presented at AUA meeting

May 5, 1999

Cantab in-licenses Novasomes adjuvant for use in TA-CIN vaccine; clinical testing in sight

April 26, 1999

Promising results reported at AACR meeting from M-Vax trial in advanced melanoma

April 21, 1999

Recombinant immunotoxin for hematological malignancies from NCI evaluated in phase I

April 20, 1999

Immunological response to GMK melanoma vaccine examined as part of phase III trial

April 19, 1999

NIH investigates next-generation cancer immunotherapeutic

April 14, 1999

Preliminary analysis of Biomira's synthetic cancer vaccine

April 13, 1999

Onyvax awarded grant for cancer vaccines

April 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...